

**EUROPEAN PATENT APPLICATION**

Application number: 89301877.0

Int. Cl. 4: **C 07 K 15/06**  
**C 12 N 15/00, A 61 K 39/395**

Date of filing: 24.02.89

Priority: 26.02.88 US 160887

Date of publication of application:  
30.08.89 Bulletin 89/35

Designated Contracting States:  
AT BE CH DE ES FR GB GR IT LI LU NL SE

Applicant: **DANA-FARBER CANCER INSTITUTE**  
44 Binney Street  
Boston Massachusetts 02115 (US)

Inventor: **Hemler, Martin E.**  
35 Ware Road  
Auburndale Massachusetts 02166 (US)

**Takada, Yoshikazu**  
9 Corey Road Apartment 8  
Brookline Massachusetts 02146 (US)

Representative: **Bass, John Henton et al**  
**REDDIE & GROSE** 16 Theobalds Road  
London WC1X 8PL (GB)

**VLA proteins.**

Three new and distinct heterodimers in the very late antigen (VLA) protein family are disclosed, namely VLA-3, VLA-4 and VLA-5, as well as monoclonal antibodies therefor. The N-terminal amino acid sequence for each of the VLA  $\alpha$  subunits is also disclosed.

EP 0 330 506 A2

## Description

## VLA PROTEINS

## Background of the Invention

This invention relates to a very late antigen (VLA) protein family isolated from human cell tissue which has extracellular matrix adhesion function.

Human very late antigen (VLA) heterodimers VLA-1 and VLA-2 have been disclosed by Hemler et al (J. Immunol. 131:334, 1983; J. Immunol. 132:3011, 1984; Eur. J. Immunol. 15: 502, 1985; J. Biol. Chem. 260:15246, 1985; J. Clin. Invest. 78:696, 1986). These are separate protein complexes of Mr 210,000/130,000 and Mr 165,000/130,000, respectively, which share a common  $\beta$  subunit of Mr 130,000, but have unique  $\alpha$  subunits. Both VLA-1 and VLA-2 appear very late after T cell activation and varying amounts of VLA-1 relative to VLA-2 are obtained during long term T cell culture. A monoclonal antibody for VLA-1, from murine hybridoma TS2/7, is sold by T Cell Sciences, Inc. for identification of long term or chronically activated T lymphocytes and thymocytes, and assessment of human T-cell function, particularly in response to antigenic and mitogenic stimuli. Detection of VLA-1 is also used for correlation and assessment of chronic autoimmune diseases, such as multiple sclerosis, systemic lupus erythematosus, and rheumatoid arthritis, as well as chronic viral infections. For example, increases in VLA-1 expression have been observed on the surface of T-cells of active multiple sclerosis patients.

## SUMMARY OF THE INVENTION

It has now been discovered that the very late antigen (VLA) protein family contains three additional heterodimers, namely VLA-3, VLA-4, and VLA-5. These have been immunopurified and the N-terminal amino acid sequence for each of the VLA  $\alpha$  subunits has been determined. The monoclonal antibody recognizing VLA-4 is also disclosed.

## Detailed Description of the Invention

In addition to the known VLA proteins, VLA-1 and VLA-2, which have been primarily used in correlation with studies on T cells, it has now been found that the VLA  $\beta$  protein subunit is expressed by nearly all human tissues and cell types and that three additional VLA proteins exist having a common  $\beta$  subunit and different but related  $\alpha$  subunits in a 1:1 ratio of  $\alpha$ : $\beta$ . The common  $\beta$  subunit has Mr 110,000 (nonreduced) and Mr 130,000 (reduced). The various  $\alpha$  subunits for VLA-3, VLA-4 and VLA-5 are identified as  $\alpha^3$  with Mr 150,000 (nonreduced), and Mr 135,000 (reduced),  $\alpha^4$  with Mr 140,000 (nonreduced) and Mr 150,000 (reduced), and  $\alpha^5$  with Mr 150,000 (nonreduced) and Mr 130,000 (reduced), respectively.

Abbreviations used throughout the specification are as follows: mAb, monoclonal antibody; VLA, very late antigen; PS, position specific; N-CAM, neural cell adhesion molecule.

## Monoclonal Antibodies (mAbs).

The mAbs TS2/7, 12F1, J143, and B-5G10, recognize the  $\alpha^1$ ,  $\alpha^2$ ,  $\alpha^3$ , and  $\alpha^4$  subunits of VLA-1, VLA-2, VLA-3, and VLA-4 respectively. The mAbs 12F1 and J143 are available from K. Pischel and V. Woods, University of California, San Diego, and R. Kantor and L. Old, Sloan-Kettering Institute for Cancer Research, NY, respectively. The mAbs TS2/7 and B-5G10 are available from M. Hemler at Dana Farber Cancer Institute, Boston, MA. The mAb A-1A5 (M. Hemler, Dana Farber Cancer Institute) specifically recognizes the  $\beta$  subunit common to all VLA proteins (J. Biol. Chem. 262:3300, 1987). The mAbs were purified from ascites fluid by 45% ammonium sulfate precipitation and then coupled to CNBr-activated Sepharose 4B (Pharmacia) at 3 mg of mAb per ml of packed beads according to the manufacturer's instructions.

## Purification of VLA-1 and VLA-3.

Fresh human placenta (from Brigham and Women's Hospital, Boston, MA) was extensively washed with ice-cold 0.9% NaCl, freed from amnion and chorion, and blotted dry. The tissue (100g, wet weight) was diced and homogenized at 0°C in 5 vol of 10mM Tris.HCl, pH 7.5/0.15 M NaCl/1mM phenylethylsulfonyl fluoride/1% Nonidet P-40 (buffer A) in a Waring blender (four 30-s bursts at 1-min intervals). The homogenate was centrifuged at 10,000 x g for 30 min, and the supernatant was loaded sequentially onto wheatgerm lectin-Sepharose (20 ml) and Ricin-Sepharose (40 ml) columns (Pharmacia). After rinsing with 10 column vol of buffer A, the bound material was eluted with buffer A containing 5% N-acetylglucosamine or 5% galactose, respectively. Combined lectin column eluate was passed through ovalbumin-Sepharose (10 ml) to clear nonspecifically adhering material, sequentially loaded onto TS2/7-Sepharose (5 ml) and J143-Sepharose (1 ml) columns, and then rinsed with 1 column vol of buffer A, 1 column vol of 50 mM NaCl/0.1% deoxycholate, and

then 10 column vol of 10 mM Tris.HCl, pH 7.5/0.15 M NaCl/0.1% deoxycholate. VLA-1 and VLA-3 were eluted from the respective columns with 50 mM diethylamine/0.1% deoxycholate/5% glycerol, pH 11.5, and the pH was immediately neutralized with 0.1 vol of 1 M Tris.HCl (pH 6.8).

#### Purification of VLA-5, VLA-2, and VLA-4.

After other VLA structures were depleted from human placenta glycoprotein preparations by TS2/7-, 12F1-, and J143-Sepharose chromatography, VLA-5 was purified from the remaining placenta glycoprotein fraction by  $\beta$ -specific A-1A5-Sepharose chromatography. VLA-2 was purified from 25 g of outdated platelets (from the Dana-Farber Institute blood bank and from the American Red Cross, Boston, MA) by 12F1-Sepharose or A-1A5-Sepharose chromatography, and VLA-4 was purified from 100 g of Molt-4 cells by B-5G10-Sepharose (5 ml) using the same procedures as described above.

#### Gel Separation and Sequence Analyses.

Aliquots of column fractions containing up to 1-2  $\mu$ g of protein were analyzed by NaDodSO<sub>4</sub>/PAGE on 7% acrylamide gels; this was followed by silver staining to assess yield and purity. Larger amounts of VLA protein (20-50  $\mu$ g) were run on preparative 5% NaDodSO<sub>4</sub>/PAGE gels, and aliquots of <sup>125</sup>I-labeled purified VLA proteins were run in adjacent lanes for use as markers to facilitate localization of separated subunits. Nonreducing preparative gels were run for VLA-3 and VLA-5 subunit separations (to prevent comigration of the  $\alpha$  and  $\beta$  subunits), whereas reducing conditions were used for VLA-1, VLA-2, and VLA-4 subunit separation. After preparative NaDodSO<sub>4</sub>/PAGE, gel slices containing  $\alpha$  subunits from each VLA complex were excised and electroeluted as described in Methods Enzymol. 91:227 (1983), and about 30-100 pmol of each was sequenced with a gas phase Applied Biosystems (Foster City, CA) 470A protein sequencer, carried out at the Harvard Microchemistry Facility (Cambridge, MA).

#### Purification of VLA Proteins.

Human placenta extract was enriched for glycoproteins and then sequential immunoaffinity column purification yielded substantial amounts of  $\alpha$  and  $\beta$  subunits of VLA-1, VLA-3, and VLA-5, lesser amounts of VLA-2, and no VLA-4. VLA-5 was purified using a  $\beta$ -chain-specific A-1A5-Sepharose column after the other VLA proteins were essentially depleted by TS2/7-, 12F1-, and J143-Sepharose chromatography. The identity of purified placenta VLA-5 was confirmed by testing its reactivity with mouse anti-VLA-5 serum; that serum was prepared against VLA-5 from the cell line K-562, in the absence of any other VLA proteins (Nature 326:607, 1987). Whereas only a small amount of VLA-2 was obtained from placenta, larger quantities of VLA-2 could be obtained from platelets, using A-1A5-Sepharose or 12F1-Sepharose. Platelets express mostly VLA-2, with a variable amount of VLA-5. Following A-1A5-Sepharose immunoaffinity purification and prior to N-terminal sequencing, the VLA-2  $\alpha^2$  subunit was readily separated from any contaminating  $\alpha^3$  subunit material by preparative NaDodSO<sub>4</sub>/PAGE using reducing conditions. Though absent from placenta and platelets, VLA-4 could be purified from the T-lymphoblastoid cell line Molt-4 using B-5G10-Sepharose. In the results obtained, the  $\alpha^4$  subunit was preferentially obtained, whereas the  $\beta$  subunit was presumably lost due to dissociation. It is believed that the  $\alpha^4$  and  $\beta$  subunits of VLA-4 are easily dissociated.

#### Comparisons of N-Terminal Amino Acid Sequences.

The sequences of the first 14 N-terminal residues of each of the VLA  $\alpha$  subunits were obtained (Table 1). They showed substantial homology, especially at positions 1-6 and 10-14. Homology between individual VLA  $\alpha$  subunits (summarized in Table 2) ranged from 21% (between  $\alpha^1$  and  $\alpha^3$ ) to 75% (between  $\alpha^2$  and  $\alpha^5$ ), with an average homology of 42% between any pair of subunits. Allowing for conservative amino acid substitutions homology between different pairs of VLA  $\alpha$  subunits is increased to an average of 59% range, 43-75%. An 80,000 M<sub>r</sub> peptide that is often coexpressed with VLA-4 yielded an N-terminal sequence identical to that shown for the  $\alpha^4$  subunit. It is believed that this 80,000 M<sub>r</sub> peptide is derived from the VLA- $\alpha^4$  subunit by proteolysis.

TABLE 1  
N-TERMINAL RESIDUE

Source of sub-unit:	1	2	3	4	5	6	7	8	9	10	11	12	13	14
VLA-1	PHE	(ASN)	VAL	ASP	VAL	LYS	ASP	SER	MET	THR	PHE	(LEU)	GLY	PRO
VLA-2	(PHE)	ASN	LEU	ASP	THR	X	GLU	ASP	ASN	VAL	(PHE)	ARG	(GLY)	(PRO)
VLA-3	(PHE)	ASN	LEU	ASP	THR	ARG	PHE	LEU	VAL	VAL	LYS	GLU	ALA	GLY
VLA-4	TYR	ASN	VAL	ASP	THR	GLU	SER	ALA	LEU	LEU	TYR	GLN	GLY	PRO
VLA-5	PHE	ASN	LEU	ASP	ALA	GLU	ALA	PRO	ALA	VAL	LEU	SER	GLY	PRO

TABLE 2

Percent homologies among VLA  $\alpha$  subunits

Subunit	VLA-1	VLA-2	VLA-3	% homology VLA-4	VLA-5
VLA $\alpha^1$	-	46(62)	21(43)	36(50)	38(54)
VLA $\alpha^2$	46(62)	-	46(54)	38(69)	75(75)
VLA $\alpha^3$	21(43)	46(54)	-	28(64)	46(54)
VLA $\alpha^4$	36(50)	38(69)	28(64)	-	46(69)
VLA $\alpha^5$	38(54)	75(75)	46(54)	46(69)	-

The percent homology is calculated by comparing the 11-14 amino acid residues from each sequence shown in Table 1 (listed at left) to the sequence for each VLA  $\alpha$  subunit (listed at top). Percent homologies including conservative amino acid substitutions are shown in parentheses. The following amino acids were considered as conservative substitutions: threonine, serine; phenylalanine, tyrosine; valine, isoleucine, leucine; aspartic acid, glutamic acid; asparagine, glutamine; arginine, lysine; and alanine, glycine.

Based on biochemical studies the VLA-4 structure has been identified as a distinct Mr 150,000/130,000  $\alpha^4\beta$  heterodimer on T lymphoblastoid cells of leukemic origin and on peripheral blood T cells. In the absence of a mAb specific for the  $\alpha^4$  subunit, VLA-4 is difficult to identify and study because: 1) the  $\alpha^4$  subunit could easily be mistaken for  $\alpha^2$ ,  $\alpha^3$  or  $\alpha^5$ , which are all similar in size (Mr 140,000-150,000) when reduced; 2) during analyses of VLA-4 using anti- $\beta$  reagents,  $\alpha^4$  could often be lost due to its apparent weak association with the  $\beta$  subunit; and 3) it has not been feasible to analyze specific cell surface expression of VLA-4.

We have now characterized a mAb which specifically recognizes VLA-4 and thus confirm the existence of VLA-4 heterodimer. Furthermore, we have used this reagent to analyze VLA-4 in terms of: 1)  $\alpha^4\beta$  subunit association; 2) cell distribution; 3) changes upon T cell activation; and 4) relation to additional peptides of Mr 80,000 and 70,000.

#### VLA Protein Purification.

Cell membranes were prepared from 100 g of the T leukemic cell line HPB-ALL, solubilized in Nonidet P-40 detergent, and then enriched for glycoproteins using sequential lentil, ricin, and wheat germ lectin affinity columns. The glycoprotein eluate from the lectin columns was applied to a column of the mAb A-1A5 coupled to Sepharose, and then after washing, the column was eluted with 50 mM diethylamine at pH 11.5. Aliquots of the purified material were analyzed by SDS-PAGE and assessed for yield and purity by the silver-staining technique.

#### Production of New Monoclonal Antibodies.

New mAb were obtained from BALB/c mice immunized intraperitoneally with immunopurified VLA-4 proteins over a 9-month period. First, A-1A5 antibody complexed with HPB-ALL protein (from 20 g of cells) was injected while absorbed onto *Staphylococcus aureus* Cowan 1 strain, and then after 1.5 months, 2-3  $\mu$ g of affinity purified VLA-4 proteins in incomplete Freund's adjuvant was injected. After an additional 5 months, *S. aureus* Cowan 1-immune complexes were again injected, followed again after 2 months by purified antigen. Four days later, mouse spleen cells were fused with P3XAg8.653 myeloma cells (J. Immunol. 123:1548, 1979) at a ratio of 10:1 according to standard techniques (Nature 266:550, 1977) and were divided into 96-well plates in hypoxanthine/aminopterin/thymidine (HAT) medium with normal mouse spleen cells as feeders. Hybridoma supernatants were screened for binding to HPB-ALL cells using  $^{125}$ I-goat anti-mouse Ig as the second antibody, and positive wells were subcloned by limiting dilution at least two times, prior to the production of ascites in pristane-primed BALB/c mice. The new mAb B-5G10 and B-5B7 were shown to be IgG1 antibodies by radial immunodiffusion using anticlass antisera. Monoclonal antibodies to VLA-3 and VLA-5 can be made in similar fashion.

#### VLA-4 Purification and mAb Production.

Since it was believed that the T lymphoblastoid cell line HPB-ALL expressed a protein heterodimer named VLA-4, distinct from VLA-1, VLA-2, or VLA-3, this protein was purified from HPB-ALL cells in two steps. First, glycoprotein enrichment was carried out using lectin-Sepharose affinity chromatography, and second, A-1A5-Sepharose chromatography was used to specifically isolate the VLA  $\beta$  protein and any attached  $\alpha$  subunits. The immunopurified material contained the VLA  $\beta$  subunit (Mr 130,000), a small amount of material in the position expected for  $\alpha^4$  (Mr 150,000), and additional material at Mr 80,000 and 70,000 as shown by silver staining. None of these protein bands appeared in a control experiment.

To obtain an anti-VLA-4 mAb, immunopurified VLA protein was used for mouse immunization, followed by hybridoma production and screening. A mAb (B-5G10) was selected because it bound to the VLA-4 positive

cell line HPB-ALL, but not to the VLA-4 negative erythroleukemic cell line K562. At the same time, another mAb (called B-5B7) was selected which bound strongly to both HPB-ALL and K-562 cells.

#### Immunoprecipitation of VLA-4 by B-5G10.

The reactivities of B-5G10 and B-5B7 were further analyzed by immunoprecipitation. Results with B-5G10 were strongly suggestive of an anti- $\alpha^4$  (and thus anti-VLA-4) specificity because: 1) B-5G10 yielded a major M<sub>r</sub> 150,000 protein identical in size to that expected for the  $\alpha^4$  subunit; 2) B-5G10 was strongly positive on a cell line (HPB-MLT) known to be positive for VLA-4 but very weak or negative for VLA-1, VLA-2, VLA-3, and VLA-5; 3) B-5G10 did not immunoprecipitate proteins from the VLA-4 negative, VLA-5-positive cell line K-562; and 4) B-5G10 recognized relatively more  $\alpha^4$  and less  $\beta$  subunit than was recognized by either mAb A-1A5, or B-5B7. In fact, the latter mAb (B-5B7) recognized mostly  $\beta$ , with little or no  $\alpha^4$  present. Consistent with  $\beta$  specificity, both B-5B7 and A-1A5 immunoprecipitated VLA  $\beta$  protein from K562. The wide variation in relative levels of  $\alpha^4$  and  $\beta$  indicate that 1) the  $\alpha^4$  and  $\beta$  subunits of VLA-4 easily dissociated and dissociation is induced by some antibodies (B-5G10, B-5B7) more readily than others A-1A5). We have found that  $\alpha^4\beta$  association can be more readily maintained if the pH is kept near or below 8.0 and/or if 0.3% CHAPS detergent is used instead of 1% Nonidet P-40.

In addition to  $\alpha^4$  and variably associated  $\beta$  subunit, B-5G10 immunoprecipitates also often contained a prominent protein of M<sub>r</sub> 80,000 and a weaker M<sub>r</sub> 70,000 peptide. It is believed that these smaller proteins of M<sub>r</sub> 70,000, M<sub>r</sub> 80,000 are derived from  $\alpha^4$  because: 1) they are serologically cross-reactive with  $\alpha^4$  but not with the VLA  $\beta$  subunit; 2) their sizes add up to the size of the M<sub>r</sub> 150,000  $\alpha^4$  subunit; 3) when present, they are usually coexpressed with  $\alpha^4$  of VLA-4 but not with VLA-1, VLA-2, VLA-3, or VLA-5; and 4) the M<sub>r</sub> 80,000 peptide has the same NH<sub>2</sub>-terminal sequences as  $\alpha^4$ .

It appears that the M<sub>r</sub> 80,000 and 70,000 proteins, like  $\alpha^4$ , can sometimes remain stably associated with the  $\beta$  subunit. For example, the M<sub>r</sub> 70,000 protein was observed to directly cross-link with  $\beta$ , and both peptides have appeared variably in immunoprecipitates obtained using anti- and mAb or hetero-sera.

The above described VLA proteins interfere with cell attachment mechanisms and thus inhibit cell binding to matrix (or cell connective) proteins such as collagen, fibronectin, and laminin. Thus, these proteins inhibit tumor cell metastasis and interfere with immune cell function. Detection of one or more of these proteins in a cell sample will enable prediction of attachment capability of cells and the preferred growth medium. The effects of oncogenes on cell attachment can also be determined by comparing the VLA presence in both natural and transformed cells. These proteins may also have application in the assessment of human T-cell function, particularly in response to antigenic and mitogenic stimuli, and in the correlation and assessment of chronic autoimmune diseases. Monoclonal antibodies to these proteins are useful to detect their presence in a sample, which would assist in the evaluation of chronically activated T cells for diagnosis of chronic diseases such as lupus erythematosus, multiple sclerosis, rheumatoid arthritis and chronic viral and bacterial infections as well as transplantation rejection.

Monoclonal antibodies recognizing VLA-3, VLA-4 and VLA-5 may be utilized in direct or indirect immunofluorescent studies utilizing conventional procedures. For example, 5  $\mu$ l (100g) of purified antibody is mixed with a 100  $\mu$ l cell suspension containing  $5 \times 10^5$  to  $1 \times 10^6$  cells of interest in 100  $\mu$ l of PBS with 0.2% BSA and 0.1% sodium azide at pH 7.4. After incubation at 4°C for 30 minutes, the mixture is diluted with about 2 ml of PBS-BSA-azide buffer, centrifuged at 300 xg for 10 minutes at 4°C, and aspirated. After discarding the supernatant, the cell pellet is resuspended in an appropriate volume of PBS-BSA azide buffer for the type of analysis, e.g. flow cytometry or fluorescence microscope, to be employed. For indirect immunofluorescence, the cell pellet is resuspended in about 100  $\mu$ l PBS-BSA-azide buffer and 50  $\mu$ l of FITC conjugated anti-mouse immunoglobulin, diluted to about 20  $\mu$ g/ml in PBS-BSA-azide buffer, are added. After incubation at 4°C for 30 minutes, the mixture is diluted, centrifuged and aspirated as described above, and the cell pellet resuspended in PBS-BSA-azide buffer as appropriate to the type of analysis selected.

#### Claims

1. The highly purified protein VLA-3 or its synthetic bioequivalent.
2. The highly purified protein VLA-4 or its synthetic bioequivalent.
3. The highly purified protein VLA-5 or its synthetic bioequivalent.
4. The highly purified alpha subunit of the protein of claims 1, 2, or 3.
5. A recombinant DNA which codes for the protein of claims 1, 2, or 3.
6. A recombinant DNA which codes for the alpha subunit of claim 4.
7. A recombinant DNA which codes for an N-terminal sequence selected from the group consisting of
  - (a) PHE ASN LEU ASP THR ARG PHE LEU VAL VAL LYS GLU ALA GLY
  - (b) TYR ASN VAL ASP THR GLU SER ALA LEU LEU TYR GLN GLY PRO
  - (c) PHE ASN LEU ASP ALA GLU ALA PRO ALA VAL LEU SER GLY PRO
8. A monoclonal antibody which has been derived from the protein of claims 1, 2 or 3 and which specifically binds to the alpha subunit thereof.
9. A monoclonal antibody which has been derived from and specifically binds to the alpha subunit of claim 4.
10. The monoclonal antibody B-5G10.



Europäisches Patentamt  
European Patent Office  
Office européen des brevets

Publication number:

**0 330 506  
A3**

12

## EUROPEAN PATENT APPLICATION

21 Application number: 89301877.0

51 Int. Cl.<sup>5</sup>: C07K 15/06, C12N 15/00,  
A61K 39/395

22 Date of filing: 24.02.89

30 Priority: 26.02.88 US 160887

43 Date of publication of application:  
30.08.89 Bulletin 89/35

84 Designated Contracting States:  
AT BE CH DE ES FR GB GR IT LI LU NL SE

88 Date of deferred publication of the search report:  
20.06.90 Bulletin 90/25

71 Applicant: DANA FARBER CANCER INSTITUTE  
44 Binney Street  
Boston Massachusetts 02115(US)

72 Inventor: Hemler, Martin E.  
35 Ware Road  
Auburndale Massachusetts 02166(US)  
Inventor: Takada, Yoshikazu  
9 Corey Road Apartment 8  
Brookline Massachusetts 02146(US)

74 Representative: Bass, John Henton et al  
REDDIE & GROSE 16 Theobalds Road  
London WC1X 8PL(GB)

54 VLA proteins.

57 Three new and distinct heterodimers in the very late antigen (VLA) protein family are disclosed, namely VLA-3, VLA-4 and VLA-5, as well as monoclonal antibodies therefor. The N-terminal amino acid sequence for each of the VLA  $\alpha$  subunits is also disclosed.

EP 0 330 506 A3



European Patent  
Office

## EUROPEAN SEARCH REPORT

Application Number

EP 89 30 1877

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int. Cl. 4)
X	THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 262, no. 24, 25th August 1987, pages 11478-11485; M.E. HEMLER et al.: "Characterization of the cell surface heterodimer VLA-4 and related peptides" * The whole document *	1-10	C 07 K 15/06 C 12 N 15/00 A 61 K 39/395
D,X	THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 262, no. 7, 5th March 1987, pages 3300-3309; M.E. HELMER et al.: "The VLA protein family" * The whole article *	1-10	
X	PROC. NATL. ACAD. SCI. USA, vol. 84, no. 10, May 1987, pages 3239-3243; Y. TAKADA et al.: "The very late antigen family of heterodimers is part of a superfamily of molecules involved in adhesion and embryogenesis"	1-10	
X	NATURE, vol. 326, no. 6113, 9th April 1987, pages 607-609; Y. TAKADA et al.: "Fibronectin receptor structures in the VLA family of heterodimers" * The whole document *	1-10	TECHNICAL FIELDS SEARCHED (Int. Cl. 4)  C 12 N A 61 K
X	EUROPEAN J. IMMUNOLOGY, vol. 16, pages 1343-1349, 1986; F. SANCHEZ-MADRID et al.: "VLA-3: A novel polypeptide association within the VLA molecular complex: cell distribution and biochemical characterization" * The whole document *	1,4,8	
The present search report has been drawn up for all claims			
Place of search THE HAGUE		Date of completion of the search 21-03-1990	Examiner PULAZZINI A.F.R.
CATEGORY OF CITED DOCUMENTS X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document		T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons ----- & : member of the same patent family, corresponding document	

EPO FORM 1503 (01.82) (P0001)



European Patent  
Office

# EUROPEAN SEARCH REPORT

Page 2

Application Number

EP 89 30 1877

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int. Cl. 4)
P,X	JOURNAL OF CELLULAR BIOCHEMISTRY, vol. 37, pages 385-393, 1988; Y. TAKADA et al.: "Extracellular matrix receptors, ECMRII and ECMRI, for collagen and fibronectin correspond to VLA-2 and VLA-3 in the VLA family of heterodimers" * The whole document *	1-10	
P,X	THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 263, no. 16, 5th June 1988, pages 7660-7665; M.E. HEMLER et al.: "Multiple very late antigen (VLA) heterodimers on platelets" * The whole document *	1-10	
P,X	CHEMICAL ABSTRACTS, vol. 110, no. 9, 27th February 1989, page 470, abstract no. 73524y, Columbus, Ohio, US; Y. TAKADA et al.: "Identification of cell adhesion receptors to fibronectin, laminin and collagen in VLA (very late antigen) family of heterodimers", & WAKAYAMA MED. REP. 1988, 30(3), 67-80 * The whole abstract *	1-10	
The present search report has been drawn up for all claims			TECHNICAL FIELDS SEARCHED (Int. Cl. 4)
Place of search THE HAGUE		Date of completion of the search 21-03-1990	Examiner PULAZZINI A.F.R.
<b>CATEGORY OF CITED DOCUMENTS</b>			
X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document		T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document	

EPO FORM 1503 01.82 (P0401)